Manipulating and Optimizing Brain Rhythms for Enhancement of Sleep
Morpheus - Manipulating and Optimizing Brain Rhythms for Enhancement of Sleep
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Karla Crockett
- Phone Number: 507-538-4880
- Email: crockett.karla@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic in Rochester
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- DBS in one of the defined nuclei of interest during the period of the study
- Be willing and able to give written and oral informed consent
- Ability to complete all required study procedures including travelling to Mayo Clinic and staying overnight
- All women of childbearing potential and women who have been amenorrheic for less than 1 year must practice effective contraception during the study. This includes a barrier method such as condom or diaphragm with spermicide; barrier intrauterine device (IUD) or abstinence.
Exclusion Criteria:
- Cognitive impairment (judged by the clinician taking consent as not having sufficient mental capacity to understand the study and its requirements). This is including anyone who, in the opinion of the clinician taking consent is unlikely to retain sufficient mental capacity for the duration of their involvement in the study.
- Patients with any other medical condition that would interfere with study conduct or make it unsafe for them to participate
- Pregnancy test positive.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Deep Brain Stimulation (DBS) system
Subjects with existing DBS systems implanted for neurological disease (e.g., Parkinson's, pain, epilepsy) will have targeted stimulation patterns during specific stages of sleep using their existing DBS device.
|
Open and closed-loop electrical modulation triggered and based on ongoing sleep staging by researcher as well as automated closed-loop algorithm for stimulation.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participants to Complete Study
Time Frame: Through study completion, approximately 1 year
|
Total number of participants to complete all scheduled study activities
|
Through study completion, approximately 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total Sleep Time
Time Frame: Baseline, post-intervention (approximately 1 night)
|
Length of sleep time reported in minutes
|
Baseline, post-intervention (approximately 1 night)
|
|
Psychomotor Vigilance Test
Time Frame: Baseline, post-intervention (approximately 1 night)
|
Measures reaction time (milliseconds) by asking subjects to press a button on an electronic device as soon as a light appears (every few seconds for 10 minutes).
|
Baseline, post-intervention (approximately 1 night)
|
|
Karolinska Sleepiness Scale
Time Frame: Baseline, post-intervention (approximately 1 night)
|
Measures subjective level of tiredness at a particular time during the day using a 9-point scoring scale of 1 = extremely alert, 3 = alert, 5 = neither alert nor sleepy, 7 = sleepy - but no difficulty remaining awake, and 9 = extremely sleepy - fighting sleep.
|
Baseline, post-intervention (approximately 1 night)
|
|
Latency to Sleep Onset
Time Frame: Baseline, post-intervention (approximately 1 night)
|
Time in minutes from beginning of study to the first stage of sleep
|
Baseline, post-intervention (approximately 1 night)
|
|
Latency to Rapid Eye Movement (REM) Sleep
Time Frame: Baseline, post-intervention (approximately 1 night)
|
Time in minutes from beginning of sleep to first REM sleep onset.
|
Baseline, post-intervention (approximately 1 night)
|
|
Number of Sleep Cycles
Time Frame: Baseline, post-intervention (approximately 1 night)
|
Total number of sleep cycles defined as switches of non-rapid eye movement (NREM) and rapid eye movement (REM) sleep.
|
Baseline, post-intervention (approximately 1 night)
|
|
Number of Awakenings Per Night
Time Frame: Baseline, post-intervention (approximately 1 night)
|
Total number of awakenings during night
|
Baseline, post-intervention (approximately 1 night)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Gregory Worrell, MD, Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 19-001216
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NCT03860298CompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant Epilepsy
-
NCT03916848Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, Focal
-
NCT06153186TerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence Epilepsy
-
NCT06310954RecruitingEpilepsy Intractable | Epilepsy in Children
-
NCT01311440CompletedEpilepsy | Generalized Epilepsy | Focal Epilepsy
-
NCT00150813CompletedEpilepsy, Tonic-clonic
-
NCT00150787CompletedEpilepsy, Tonic-clonic
-
NCT06602570Not yet recruitingEpilepsy Intractable | Epilepsy in Children
-
NCT03278210CompletedFocal Epilepsy | Epilepsy Intractable
-
NCT04569708CompletedEpilepsy | Epilepsy; Seizure | Rolandic Epilepsy | Rolandic Epilepsy, Benign | Centrotemporal Epilepsy | Centrotemporal; EEG Spikes, Epilepsy of Childhood
Clinical Trials on DBS Stimulation during sleep
-
NCT06164717Recruiting
-
NCT06386588Recruiting
-
NCT02608840CompletedMild Cognitive Impairment
-
NCT06608875Recruiting
-
NCT06466772Recruiting
-
NCT07250685Not yet recruiting
-
NCT03377569Active, not recruitingParkinson Disease | REM Behavior Disorder
-
NCT07110376Recruiting
-
NCT02881151CompletedTBI (Traumatic Brain Injury)